Everything you need to know
about biosimilars in one place

Lilly Set to Launch Lantus Biosimilar in the US Next Year

Eli Lilly and Sanofi have agreed terms in a patent dispute revolving around insulin glargine which will ward off the launch of a biosimilar to Sanofi’s Lantus brand until the end of next year.   The settlement relates to patents covering Sanofi’s Lantus SoloSTAR formulation of the basal insulin, a pen injector version which accounts … Continue reading Lilly Set to Launch Lantus Biosimilar in the US Next Year

Read more

What Do Gastroenterologists Think About Biosimilars?

The American Gastroenterological Association surveyed 180 of its members on biosimilars and biologics.   In late July, the American Gastroenterological Association released findings from a national survey of gastroenterologists on biosimilars and biologics. Biologics are used regularly for the treatment of inflammatory bowel disease (IBD), and biosimilars for the treatment of IBD, such as Remsima/Inflectra … Continue reading What Do Gastroenterologists Think About Biosimilars?

Read more

Global Biosimilar Market to Reach $6.22 Million by 2020, Says Report

A new report predicts the global biosimilars market will reach $6.22 billion by 2020, and examines the drivers and impediments to its growth.   According to a new market research report, the global biosimilars market will reach $6.22 billion by 2020, up from $2.29 billion in 2015, at a compound annual growth rate (CAGR) of … Continue reading Global Biosimilar Market to Reach $6.22 Million by 2020, Says Report

Read more

Samsung Proving a Fierce Contender in Biosimilars Race

With the recent clinical trial success of the joint Merck/Samsung Bioepis Humira biosimilar, SB5, the drug development partners are setting their sights on European approval. As AbbVie’s blockbuster Humira nears patent expiry, Merck and Samsung Bioepis seem ready to corner the market with their version of the best-selling injectable drug, which is used to treat … Continue reading Samsung Proving a Fierce Contender in Biosimilars Race

Read more

South Korea Comes to the Fore in Biosimilars Space

Aided by government funding and big pharma partnerships, South Korea is staking its claim on biosimilars, with Celltrion and Samsung the main contenders.   South Korea is pushing to be a leader in the biopharmaceuticals field, so says a recent Financial Times report. While that country’s Celltrion is already a big player in manufacturing, partnering … Continue reading South Korea Comes to the Fore in Biosimilars Space

Read more

Biosimilars Still Hold Cost-Cutting Promise Say Pundits

Experts say the future of biosimilars in the U.S. still looks hopeful, despite current roadblocks to their market entry.   With Zarxio’s entry into the U.S. market still stalled by legal battles, many experts are still optimistic about the potential of biosimilars, especially in easing health care spending – once they enter the market, that … Continue reading Biosimilars Still Hold Cost-Cutting Promise Say Pundits

Read more

Stakeholder Impact Study to Look at Oncology Biosimilars

Global medical market research company, Ipsos Healthcare in May launched a syndicated study to highlight the impact of biosimilars on treating cancer patients.   Known as the Multi-Stakeholder Biosimilar Impact Study, it follows the firm’s successful launch of a 2014 syndicated Biosimilar Impact Study in the autoimmune field. The study has been developed in response … Continue reading Stakeholder Impact Study to Look at Oncology Biosimilars

Read more

Report Reveals US Payer Perspectives on Biosimilars

A recent report offers payers’ insights into the U.S. biologics market, and the impact biosimilars will have on it.   With spending on biologics set to reach $100 billion in the U.S. over the next couple of years, biosimilars are seen as a offering potential relief for healthcare system financial pressures of declining resources, increasing … Continue reading Report Reveals US Payer Perspectives on Biosimilars

Read more